High-Pd-L1 Tumor Expression

NATIONAL HARBOR, Md. — Patients who received atezolizumab as first-line monotherapy for metastatic non-small-cell lung cancer showed significant improvement in overall survival, according to phase 3 interim overall survival analysis data of the IMpower 110 trial presented at Society for Immunotherapy of Cancer Annual Meeting.